Subscribe To

Price Alert Latest News Economic Calendar News

EXAS / Exact Sciences set to rally on positive top-line results from pivotal BLUE-C study

Exact Sciences (NASDAQ:EXAS) shares rose in Wednesday pre-market trading after the molecular diagnostics company specializing in the detection of early-stage cancers announced positive top-line results from its pivotal BLUE-C study. The company said the results show that its next-generation Cologuard test demonstrated 94% sensitivity for colorectal cancer at 91% specificity, raising the bar in non-invasive screening. Read More

Demo Live Account See Partner Details

Content Topics

Exact

Sciences

Rally

Positive

Top

Line

Results

From

Pivotal

Top line

Blue c

Stock

EXAS

Posted: Jun 21 2023, 08:14

Author Name: Proactive Investors

EXAS News

By Zacks Investment Research
November 2, 2023

Exact Sciences (EXAS) Q3 Earnings Beat, Gross Margin Rises

Exact Sciences' (EXAS) Screening revenue upside is primarily attributable to broad-based momentum in Cologuard adoption.

By InvestorPlace
October 23, 2023

3 Comeback Stocks to Buy Before They Soar Again in 2024

Many investors are probably upset that the yields of the 10-year treasury bonds are trading around 5%. It's true that higher bond yields do increases

By InvestorPlace
October 16, 2023

Cathie Wood's 3 Favorite AI Stocks: October 2023

At the end of September, Cathie Wood sat down with Morningstar to discuss the current and future state of Ark Invest, including the investment managem

By Zacks Investment Research
October 11, 2023

Here's Why You Should Retain Exact Sciences (EXAS) Stock Now

Investors remain optimistic about Exact Sciences (EXAS) due to its strategic prioritization and positive solvency.

By PRNewsWire
October 9, 2023

Exact Sciences schedules third quarter 2023 earnings call

MADISON, Wis. , Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today a

By PRNewsWire
October 9, 2023

Exact Sciences to Present Late-Breaking Data from Pivotal BLUE-C Study on Next-Generation Cologuard at ACG 2023

MADISON, Wis. , Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, t

By The Motley Fool
October 8, 2023

Which Is the Better Cancer-Testing Healthcare Stock: Exact Sciences or Guardant Health?

Exact Sciences and Guardant Health have both enjoyed triple-digit revenue growth over the past five years. Exact Sciences' shares are up more than 31%

By Zacks Investment Research
October 3, 2023

Exact Sciences (EXAS) Aided by Innovation, Strategic Buyouts

Exact Sciences (EXAS) is planning several key milestones to bring six innovative cancer diagnostics from its pipeline to patients in need.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.